Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical XXXX .

@entity1 @entity4634 @entity632 @entity2699 @entity1732 @entity8395 @entity1349 @entity978 @entity14797 @entity5713
UNASSIGNED: @entity8395 ( @entity8395 ) inhibitor may be therapeutic in @entity1 with relapsed or refractory @entity978 ( @entity978 ). This study examined the prognostic significance of @entity8395 and two @entity8395 ligands ( @entity4634 and @entity14797 ) in uniformly treated @entity978 . Diagnostic tissues from 109 @entity978 @entity1 treated with a @entity632 , @entity1732 , @entity5713 , and @entity2699 regimen were evaluated retrospectively by immunohistochemical analysis of @entity4634 , @entity14797 , and @entity8395 expressions. The median follow-up time was 4.91  years (range, 0.17-17.33  years). Thirteen @entity1 (11  %) expressed @entity8395 protein in the peritumoral microenvironment, which was associated with poor @entity1349 ( @entity1349 ) (P   =   0.017). @entity4634 or @entity14797 expression was not associated with @entity1349 . There was no correlation between @entity4634 and @entity8395 expression or between @entity14797 and @entity8395 expression. Multivariate analysis identified @entity8395 protein as an independent prognostic factor for @entity1349 (P   =   0.019). Subgroup analysis according to the Ann Arbor stage of @entity978 showed that @entity8395 protein expression had a prognostic value in limited-stage @entity978 (P   =   0.048). @entity8395 is an independent prognostic factor in @entity978 and may allow the identification of a subgroup of @entity1 with limited-stage @entity978 who require more intensive therapy and who may benefit from anti- @entity8395 agents.
